# Boston Scientific Corporation (BSX) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $47.80, market value $69.3 billion.

## Valuation
- **P/E (trailing): 19.4×** (5-yr avg 67.8×, 3-yr avg 58.2×). Boston Scientific Corporation trades at 19.4× trailing earnings, well below its own five-year average of 67.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.25**. A PEG of 0.25 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.1×**. Enterprise value is 12.1× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.2%** (5-yr avg 2.0%). Free cash flow equals 5.2% of the market value, above its five-year average of 2.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 5.2%**. The inverse of the P/E: 5.2% of the price is earned each year.

## Profitability
- **Gross margin: 69.9%**. Boston Scientific Corporation keeps 69.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 19.8%**. 19.8% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 14.4%**. 14.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.9%**. 11.9% on shareholders' equity is solid.
- **Return on invested capital: 14.5%**. Return on all capital, debt included, is 14.5%.
- **Return on assets: 8.4%**. Each dollar of assets produces 8.4% of profit.

## Growth
- **Revenue growth (1 yr): 19.9%** (3-yr 16.5%/yr, 5-yr 15.2%/yr). Revenue grew 19.9% over the last year, against 15.2% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 55.2%** (3-yr 62.8%/yr). Earnings per share rose 55.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 57.4%/yr**. Free cash flow has compounded at 57.4% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Boston Scientific Corporation holds more cash than debt.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Boston Scientific Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (29 analysts). 29 analysts cover Boston Scientific Corporation; the consensus is buy, with an average price target of $62.69 (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -55.4%** (YTD -49.9%, 3-mo -1.5%). The shares are down 55.4% over twelve months including dividends.
- **From 52-week high: -56.3%** (13.3% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 0.17** (volatility 37%). Beta of 0.17 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BSX · Page: https://foliofundamentals.com/stocks/bsx

Not investment advice.